Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Helio Silva SaderRodrigo Elisandro MendesCecilia Godoy CarvalhaesJohn H KimbroughMariana CastanheiraPublished in: Open forum infectious diseases (2023)
The frequencies of MBL and OXA-48-type producers increased markedly. Aztreonam-avibactam demonstrated potent and consistent activity against Enterobacterales across infection types and over time.